Advanced search
Publication Cover
HIV Clinical Trials Volume 18, 2017 - Issue 2
Submit an article Journal homepage
313
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

Maria SaumoyHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, SpainCorrespondence[email protected]
,
Juan M. TiraboschiHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain
,
Jordi Ordoñez-LlanosBiochemistry Department, Biomedical Research Institute IIB Sant Pau, Barcelona, Spain
,
Esteban RiberaInfectious Disease Service, Hospital Universitari Vall d’Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain
,
Pere DomingoDepartment of Infectious Diseases, Hospitals Universitaris Arnau de Vilanova & Santa Maria, Institut de Recerca Biomèdica (IRBLLEIDA), Universitat de Lleida, Lleida, Spain
,
Josep MallolasInfectious Disease Service, Hospital Clínic, Barcelona, Spain
,
Jordi CurtoHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain
,
Josep M. GatellInfectious Disease Service, Hospital Clínic, Barcelona, Spain
&
Daniel PodzamczerHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain
 show all
Pages 49-53 | Published online: 12 Jan 2017

References

  • Baril J-G, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with hiv: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. Plos one. 2016;11:e0148231.10.1371/journal.pone.0148231
  • Arribas JR, Girard P-M, Paton N, et al. Efficacy of protease inhibitor monotherapy vs triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016;17:358–367.10.1111/hiv.12348
  • Arribas JR, Girard P-M, Landman R, et al. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–792.10.1016/S1473-3099(15)00096-1
  • Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:775–784.10.1016/S1473-3099(15)00097-3
  • Santos JR, Saumoy M, Curran A, et al. the lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:403–408.10.1093/cid/civ296
  • Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215–224.10.1016/j.cca.2012.09.010
  • Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
  • Freedman DS, Otvod JD, Jeyarajah EJ, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham study. Clin Chem. 2004;50:1189–1200.10.1373/clinchem.2004.032763
  • Saumoy M, Ordoñez-Llanos J, Martínez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther. 2011;16:459–468.10.3851/IMP1785
  • Mangili A, Ahmad R, Wolfert RL, et al. Lipoprotein-associated phospholipase a2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis. 2014;58:893–900.10.1093/cid/cit815
  • Papakonstantinou VD, Chini M, Mangafas N, et al. In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients. Lipids Health Dis. 2014;13:90–99.10.1186/1476-511X-13-90

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.